Highlights
A collection of news and information related to GlaxoSmithKline PLC published by this site and its partners.
Displaying items 1-12 of 142
» View wsbtradio.com items only
1
2
3
4
5
6
7
8
9
10
11-12
•
Next >
-
Wall Street posts first weekly loss since mid-April on Fed angst
ReutersNEW YORK (Reuters) - The S&P 500 declined for a third day on Friday, with the three major stock indexes posting their first negative week since mid-April on lingering concern that the central bank may scale back its stimulus measures to support the...Tags: Germany, House Building, U.S. Department of Energy, Upstream Oil and Gas Activities, Edward Jones
-
RPT-FEATURE-Pfizer takes its shot at a vaccine for evasive superbug
ReutersBy Julie Steenhuysen CHICAGO, May 23 (Reuters) - Kathrin Jansen is a microbiologist with at least two breakthrough vaccines to her name: she brought the cervical cancer vaccine Gardasil to market for Merck and helped develop the $4 billion a year...Tags: Penicillin (drug), Meningitis, Merck & Company Incorporated, Vaccines, Nabi
-
GSK flu shot may raise adult narcolepsy risk: Finnish scientists
ReutersHELSINKI/LONDON (Reuters) - GlaxoSmithKline Plc's H1N1 pandemic flu shot may put adults at higher risk of developing narcolepsy, not only children as previous studies found, Finland's National Institute for Health and Welfare said on Thursday. Growing...Tags: Finland, Vaccines, Epidemics and Plagues, Flu Vaccine, Swine Flu
-
Elan rejects Royalty's $6.4 billion raised offer
ReutersDUBLIN (Reuters) - Elan rejected Royalty Pharma's increased $6.4 billion bid on Thursday, shortly after the U.S. firm cut the acceptance bar for its latest offer to 50 percent plus one share. Royalty raised its hostile cash bid to $12.50 per share on...Tags: Humira (drug), Biogen Idec Incorporated, Elan Corporation Plc, Multiple Sclerosis, Rheumatoid Arthritis
-
Royalty eleva oferta por Elan, emite ultimátum a accionistas
ReutersPor Padraic Halpin y Jessica Toonkel DUBLIN/NUEVA YORK (Reuters) - Royalty Pharma elevó su oferta hostil por Elan a 12,50 dólares por acción y amenazó con retirar la oferta si los accionistas de Elan aprueban una serie de transacciones defensivas...Tags: Elan Corporation Plc, Theravance Incorporated
-
Immune system cancer drugs tipped to be a $35 bln market
Reuters* Potential sales of $35 bln a year over next 10 years - Citigroup * Immunotherapy may be used in up to 60 percent of cancers * Bristol-Myers Squibb and Roche both upgraded to "buy" By Ben Hirschler LONDON, May 22 (Reuters) - A new wave of medicines...Tags: Merck & Company Incorporated, Vaccines, Food and Drug Administration, Citigroup Incorporated, HIV
-
Immune system cancer drugs tipped to be a $35 billion market
ReutersLONDON (Reuters) - A new wave of medicines that tap the power of the immune system to fight cancer could become the biggest drug class in history, with potential sales of $35 billion a year. That bullish sales forecast by analysts at U.S. bank...Tags: Merck & Company Incorporated, Vaccines, Food and Drug Administration, Citigroup Incorporated, HIV
-
U.S. government taps GlaxoSmithKline for new antibiotics
ReutersLONDON, May 22 (Reuters) - The U.S. government has signed an antibiotics development deal worth up to $200 million with GlaxoSmithKline to tackle the dual threats of drug resistance and bioterrorism. The collaboration, the first of its kind between...Tags: Science and Technology, Chemical Industry, Science, Medical Specialization, Pharmaceuticals
-
Inmunoterapia contra el cáncer podría ser un mercado de 35.000 mln dlrs anuales
ReutersPor Ben Hirschler LONDRES, 22 may (Reuters) - Una nueva ola de medicinas que emplea el poder del sistema inmunológico para luchar contra el cáncer podría convertirse en el mayor grupo de medicamentos de la historia, con ventas potenciales de 35.000...Tags: Merck & Company Incorporated, Citigroup Incorporated, Amgen Inc., Novartis AG, AstraZeneca Plc
-
Gobierno de EEUU firma acuerdo con GlaxoSmithKline para nuevos antibióticos
ReutersLONDRES, 22 mayo (Reuters) - El Gobierno de Estados Unidos firmó un acuerdo para desarrollo de antibióticos valorado en más de 200 millones de dólares con GlaxoSmithKline para enfrentar la doble amenaza de la resistencia a los fármacos y el... -
US high-yield issuers rush to market
ReutersBy Joy Ferguson and Rachelle Kakouris May 20 (IFR) - It's looking like another busy week for high-yield as issuers rush in ahead of the long Memorial Day weekend to take advantage of the current window for issuance at near-record low coupons. A total...Tags: Mortgages, Petroleum Industry, Health Treatments, Radiation Therapy, Prices
-
XenoPort to drop multiple sclerosis drug, shares fall
Reuters(Reuters) - XenoPort Inc said it would stop development of an experimental multiple sclerosis treatment it planned to launch in 2015 after a late-stage trial failed to show significant improvement over a placebo. Shares of the company fell 26 percent...Tags: Food and Drug Administration, Stock Activities, Environmental Issues, Biogen Idec Incorporated, Multiple Sclerosis
May 24, 2013
|Story| Reuters
May 23, 2013
|Story| Reuters
May 23, 2013
|Story| Reuters
May 23, 2013
|Story| Reuters
May 20, 2013
|Story| Reuters
May 22, 2013
|Story| Reuters
May 22, 2013
|Story| Reuters
May 22, 2013
|Story| Reuters
May 22, 2013
|Story| Reuters
May 22, 2013
|Story| Reuters
May 20, 2013
|Story| Reuters
May 20, 2013
|Story| Reuters
Original site for GlaxoSmithKline PLC topic gallery.